Specialist pharmaceutical company ViiV Healthcare has boosted its HIV portfolio following a multimillion dollar deal with Bristol-Myers Squibb.
The company, which has GlaxoSmithKline as a majority shareholder, has acquired Bristol-Myers Squibb’s HIV research and development assets and its preclinical and discovery stage research assets.
The deal, announced on 22 February 2016, means ViiV now has one of the most “robust HIV pipelines” in the industry, according to the company’s chief executive officer Dominique Limet.
“The assets that we have acquired complement our existing portfolio and could lead to new medicines and combinations addressing a broad range of treatment and prevention needs of people living with HIV,” he says.
Drugs in development, which now pass to ViiV, include phase lll fostemsavir, an attachment inhibitor for heavily treated patients that is expected to begin the US marketing approval process in 2018; preclinical and discovery phase products include a novel biologic with a triple mechanism of action.
ViiV Healthcare paid an initial US$317m upfront for the late stage HIV assets, with another US$518m for development and first commercial sale milestones as well as tiered royalties on sales.
Some US$33m was paid upfront for the preclinical and discovery stage assets and another US$587m to cover development and first commercial sales milestones.